SEARCH

SEARCH BY CITATION

References

  • 1
    Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment and control of hypertension, 1988–2008. JAMA. 2010;303:20432051.
  • 2
    Vincent GK, Vellcoff VA. The next four decades: the older population in the US: 2010 to 2050: population estimates and projections. Curr Population Reports. Washington, DC: US Department of Commerce, 2010:251138. Available on the Internet at: http:www.aoa.gov/aoaroot/aging_statistics/future_growth/DOCS/p25-1138.pdf. Accessed December 21, 2012.
  • 3
    Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics – 2013 update. A report from the American Heart Association. Circulation. 2013;126:e1e256; published online December 12, 2012: available on the internet at http://www.circ.ahajournals.org/content/early/2012/12/12/CIR.0b013e31828124ad.citation. Accessed December 20, 2012.
  • 4
    Murphy SL, Xu J, Kochanek KD. Deaths: preliminary data for 2010. Natl Vital Stat Rep. 2012;60:1112. Hyattsville, MD: National Center for Health Statistics, 2012. Available on the Internet at: http://www.cdc.gov/nchs/data/nvsr/nvsr60/nvsr60_04.pdf. Accessed December 21, 2012.
  • 5
    Fang J, Alderman MH, Keenan NL, Ayala C, Croft JB. Hypertension control at physicians' offices in the United States. Am J Hypertens. 2008;21:136142.
  • 6
    National Committee for Quality Assurance. State of Health Care Quality. 2010:20, Available at: http://www.web.ncqa.org/portals/0/state%of%health%care/2010/ sohc$202010%20-%20full2.pdf. Accessed December 20, 2012.
  • 7
    American Diabetes Association. Standards of medical care in diabetes – 2011. Diabetes Care. 2011;34(suppl 1):S11S61, especially pages S27–S29.
  • 8
    Levey AS, Rocco MV, Anderson S, et al. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis. 2004;43(suppl 1):S1S290.
  • 9
    Rosendorff C, Black HR, Cannon CP, et al. Treatment of hypertension in the prevention and management of ischemic heart disease. A Scientific Statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation. 2007;115:27612788.
  • 10
    Elliott WJ. What should be the blood pressure target for diabetics? Curr Opin Cardiol. 2011;26:308313.
  • 11
    American Diabetes Association. Standards of medical care in diabetes – 2013. Diabetes Care. 2013;36:S11S66.
  • 12
    Persell S. Prevalence of resistant hypertension in the United States. Hypertension. 2011;57:10761080.
  • 13
    Egan B, Zhao Y, Axon R, Brzezinski WA, Ferdinand KC. Uncontrolled and apparent treatment resistant hypertension in the United States, 1988–2008. Circulation. 2011;124:10461058.
  • 14
    Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension. 2008;51:14031419.
  • 15
    Roberie DR, Elliott WJ. What is the prevalence of resistant hypertension in the United States? Curr Opin Cardiol. 2012;27:386391.
  • 16
    Vidt DG. Contributing factors in resistant hypertension. Truly refractory disease is rarely found in a properly-conducted workup. Postgrad Med. 2000;107:5760.
  • 17
    Yakovlevitch M, Black HR. Resistant hypertension in a tertiary care clinic. Arch Intern Med. 1991;151:17861792.
  • 18
    Garg JP, Elliott WJ, Folker A, Izhar M, Black HR for the RUSH University Hypertension Service. Resistant hypertension revisited: a comparison of two university-based cohorts. Am J Hypertens. 2005;18:619626.
  • 19
    Taler SJ, Textor SC, Augustine JE. Resistant hypertension: comparing hemodynamic management to specialist care. Hypertension. 2002;39:982988.
  • 20
    Odama U, Singer G, Morrissey M, Elliott WJ, Black HR. Predictors of hypertension control in a specialty clinic [abstract]. Am J Hypertens. 2000;13:19A.
  • 21
    Izhar M, Elliott WJ, Singer G, et al. Prevalence and control of cardiovascular risk factors in a tertiary hypertension clinic [abstract]. Am J Hypertens. 2001;14:247A.
  • 22
    Garg JP, Elliott WJ, Izhar M, et al. Lack of performance-related bias in blood pressure measurements in a hypertension clinic [abstract]. Am J Hypertens. 2002;15:A91.
  • 23
    Ellis R, Elliott WJ, Izhar M, et al. Medication utilization to achieve goal blood pressure in a tertiary hypertension clinic [abstract]. Am J Hypertens. 2003;16:34A.
  • 24
    Chua DY, Behara R, Meyer P, et al. Prevalence of antihypertensive drug monotherapy at a specialty hypertension clinic [abstract]. Am J Hypertens. 2004;17:103A.
  • 25
    Choi KL, Bakris GL, Black HR, Neri GS, Elliott WJ. Predictors of goal blood pressure achievement in patients with hypertension only or kidney disease and/or diabetes in a tertiary hypertension center [abstract]. Am J Hypertens. 2005;18:103A104A.
  • 26
    Khosla N, Kravitz G, Singer G, et al. Factors predicting achievement of goal blood pressure in a tertiary hypertension center [abstract]. J Clin Hypertens (Greenwich). 2006;8:A90A91.
  • 27
    Chugh AR, Elliott WJ, Kravitz G, Black HR, Bakris GL. Predictors of controlled blood pressure and LDL-cholesterol levels in a tertiary hypertension center [abstract]. J Clin Hypertens (Greenwich). 2007;9:A55.
  • 28
    Elliott WJ, Eaton C, Rucker-Whitaker C, Liebson PR. Impact of HEDIS 2007 on blood pressure control rates in a tertiary hypertension center [abstract]. J Clin Hypertens (Greenwich). 2008;10(suppl A):A68.
  • 29
    Khosla N, Kravitz G, Singer G, et al. Controlling cardiovascular risk factors to target in a tertiary hypertension center [abstract]. J Clin Hypertens (Greenwich). 2006;8:A91.
  • 30
    Chugh AR, Elliott WJ, Kravitz G, Black HR, Bakris GL. Blood pressure, LDL-cholesterol, and A1c target achievement among diabetics in a tertiary hypertension center [abstract]. J Clin Hypertens (Greenwich). 2007;9:A55.
  • 31
    Rucker-Whitaker C, Eaton C, Liebson PR, Elliott WJ. Cardiovascular risk factor control in a tertiary hypertension center [abstract]. J Clin Hypertens (Greenwich). 2008;10(suppl A):A142.
  • 32
    Okonofua EC, Simpson K, Jesri A, et al. Therapeutic inertia is an impediment to achieving the Healthy People 2010 blood pressure control goals. Hypertension. 2006;47:17.
  • 33
    Egan BM, Lackland DT, Igho-Pemu P, et al. Cardiovascular risk factor control in communities – update from the ASH Carolinas-Georgia Chapter, the Hypertension Initiative, and the Community Physicians' Network. J Clin Hypertens (Greenwich). 2006;12:879886.
  • 34
    Egan BM, Zhao Y, Rehman SU, et al. Treatment resistant hypertension in a community-based practice network [abstract]. J Clin Hypertens (Greenwich). 2009;11:A6.
  • 35
    Basile JN, Lackland DT, Basile JM, Riehle JE, Egan BM. A statewide primary care approach to cardiovascular risk factor control in high-risk diabetic and non-diabetic patients with hypertension. J Clin Hypertens (Greenwich). 2004;6:1825.
  • 36
    Rehman SU, Hutchison FN, Hendrix K, Okonofua EC, Egan BM. Comparison of ethnic differences in blood pressure control at VA and non-VA sites. Arch Intern Med. 2005;165:10411047.
  • 37
    Sheats N, Lin Y, Zhao W, et al. Prevalence, treatment, and control of hypertension among African Americans and Caucasians at primary care sites for medically underserved patients. Ethn Dis. 2005;15:2532.
  • 38
    Hendrix KH, Riehle JE, Egan BM. Ethnic, gender, and age-related differences in treatment and control of dyslipidemia in hypertensive patients. Ethnic Dis. 2005;15:1116.
  • 39
    Hendrix KH, Mayhan S, Egan BM. Gender- and age-related differences in treatment and control of cardiovascular risk factors among high-risk patients with angina. J Clin Hypertens (Greenwich). 2005;7:386394.
  • 40
    Riehle JE, Lackland DT, Okonofua EC, Hendrix KH, Egan BM. Ethnic differences in treatment and control of hypertension in patients with diabetes. J Clin Hypertens (Greenwich). 2005;7:445454.
  • 41
    Hendrix KH, Mayhan S, Lackland DT, Egan BM. Demographic differences in the prevalence and treatment of chest pain syndromes and in the control of cardiovascular risk factors: a comparison of hypertensive patients with and without chest pain. Am J Hypertens. 2005;18:10261032.
  • 42
    Egan BM, McKinney WE, Zhao Y, Thomas JC. Race and gender disparities in lipid treatment and control: differences between dyslipidemic patients with and without diabetes mellitus [abstract]. J Clin Hypertens (Greenwich). 2009;11:A112.
  • 43
    Egan BM, Lackland DT, Wagner S, Gaffney TE. Multiple risk factor control in diabetic, dyslipidemic hypertensive patients [abstract]. J Clin Hypertens (Greenwich). 2009;11:A112.
  • 44
    Egan BM, Shaftman SR, Wagner CS, Bandyopadhyay D, Szymanski KA. Demographic differences in the treatment and control of glucose in type 2 diabetic patients: implications for health care practice. Ethn Dis. 2012;22:2937.
  • 45
    Egan BM, Lackland DT, Basile JN. American Society of Hypertension Regional Chapters: leveraging the impact of the clinical hypertension specialist in the local community. Am J Hypertens. 2002;15:372379.
  • 46
    Egan BM, Bandyopadhyay D, Shaftman SR, et al. Initial monotherapy and combination therapy and hypertension control – the first year. Hypertension. 2012;59:11241131.
  • 47
    Trogdon JG, Callaire BT, Egan BM, Lackland DT, Masters D. Training providers in hypertension guidelines: cost-effectiveness evaluation of a continuing medical education program in South Carolina. Am Heart J. 2011;162:786793.
  • 48
    Allaire BT, Trogdon JG, Egan BM, Lackland DT, Masters D. Measuring the impact of a continuing medical education program on patient blood pressure. J Clin Hypertens (Greenwich). 2011;13:517522.
  • 49
    Egan BM, Laken MA, Shaun Wagner C, et al. Impacting population cardiovascular health through a community-based practice network: update on an ASH-supported collaborative. J Clin Hypertens (Greenwich). 2011;13:543550.
  • 50
    Elliott WJ, Egan BM, Giles TD, Bakris GL, Sansone TM. Hypertension specialists' current and potential impact on resistant hypertension in the Medicare population [abstract]. J Clin Hypertens (Greenwich). 2011;13(suppl 1):A153.